GPT and hepatocellular carcinoma: Moreover, compared with HCC patients without virus infection, Nivolumab (anti-PD-1) treatment potentially increased higher levels of the serum ALT/AST in HCC patients with HBV/HCV virus infection, implying that ICB treatment could damage more hepatocytes in viral infected HCC patients [10].